Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 273 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014', provides an overview of the Graft Versus Host Disease (GVHD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Graft Versus Host Disease (GVHD) Overview 9
Therapeutics Development 10
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 10
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 11
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 12
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 16
Graft Versus Host Disease (GVHD) - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Graft Versus Host Disease (GVHD) - Products under Development by Companies 22
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 25
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 26
F. Hoffmann-La Roche Ltd. 26
Biogen Idec Inc. 27
Athersys, Inc. 28
Seattle Genetics, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Idera Pharmaceuticals, Inc. 32
Mesoblast Limited 33
Jazz Pharmaceuticals plc 34
Alexion Pharmaceuticals, Inc. 35
Soligenix, Inc. 36
NeoStem, Inc. 37
Pharmacyclics, Inc. 38
Pluristem Therapeutics Inc. 39
MediPost Co., Ltd. 40
Kamada Ltd. 41
R-Tech Ueno, Ltd. 42
Omni Bio Pharmaceutical Inc. 43
Alder Biopharmaceuticals Inc. 44
MSM Protein Technologies, Inc. 45
Tobira Therapeutics, Inc. 46
Bellicum Pharmaceuticals, Inc. 47
REGiMMUNE Corporation 48
Adienne Pharma & Biotech 49
Dr. Falk Pharma GmbH 50
Lycera Corp. 51
Neopharm Ltd. 52
Pharmicell Co., Ltd. 53
Sigmoid Pharma Ltd. 54
Targazyme, Inc. 55
Kymab Limited 56
Enlivex Therapeutics Ltd 57
Apceth GmbH & Co. KG 58
Generon (Shanghai) Corporation Ltd. 59
Kadmon Corporation, LLC 60
Escape Therapeutics, Inc. 61
ImmuNext, Inc. 62
Spherium biomed S.L. 63
Graft Versus Host Disease (GVHD) - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
remestemcel-L - Drug Profile 76
budesonide - Drug Profile 78
inolimomab - Drug Profile 81
anti-thymocyte globulin (rabbit) - Drug Profile 82
JR-031 - Drug Profile 84
bortezomib - Drug Profile 86
KD-025 - Drug Profile 91
natalizumab - Drug Profile 92
beclomethasone dipropionate - Drug Profile 94
aldesleukin - Drug Profile 96
RGI-2001 - Drug Profile 98
Alpha-1 Antitrypsin - Drug Profile 100
Begedina - Drug Profile 102
ALXN-1007 - Drug Profile 103
Alpha-1 Antitrypsin - Drug Profile 104
ibrutinib - Drug Profile 105
panobinostat - Drug Profile 110
clazakizumab - Drug Profile 116
Promostem - Drug Profile 118
ApoCell - Drug Profile 119
alpha-1-proteinase inhibitor (human) - Drug Profile 120
BPX-501 - Drug Profile 124
cannabidiol - Drug Profile 125
Cell Therapy for Graft Versus Host Disease - Drug Profile 126
T-Guard - Drug Profile 127
Stem Cell Therapy for Graft Versus Host Disease - Drug Profile 129
Stem Cell Therapy for GVHD - Drug Profile 130
Stem Cell Therapy for Ear Nose Throat Disorders and GVHD - Drug Profile 131
brentuximab vedotin - Drug Profile 132
MultiStem - Drug Profile 137
erismodegib - Drug Profile 140
Homeo-GH - Drug Profile 143
T-Cell Therapeutic Program - Drug Profile 144
F-652 - Drug Profile 145
Recombinant Coversin - Drug Profile 146
cyclosporine IR + cyclosporine CR - Drug Profile 147
Cell Therapy for Graft Versus Host Disease - Drug Profile 148
cenicriviroc - Drug Profile 149
defibrotide - Drug Profile 151
LYC-30937 - Drug Profile 154
Bz-423 - Drug Profile 155
ImmuStem - Drug Profile 156
IMO-8400 - Drug Profile 157
PLX-BMP - Drug Profile 159
Protein to Activate TLR5 for Rotavirus Infections and GVHD - Drug Profile 162
Fc-Alpha-1 Antitrypsin - Drug Profile 163
Alecmestencel-L - Drug Profile 164
TZ-101 - Drug Profile 165
RO-2959 - Drug Profile 167
Cell Therapy for Graft-Versus Host Disease - Drug Profile 168
MSM-707 - Drug Profile 169
FcAAT-3 - Drug Profile 170
FcAAT-2 - Drug Profile 171
Drugs for Graft Versus Host Disease - Drug Profile 173
Cell Therapy for Graft versus Host Disease - Drug Profile 174
KY-1005 - Drug Profile 175
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 176
IT-603 - Drug Profile 178
IT-901 - Drug Profile 179
disermolide - Drug Profile 180
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile 182
SP-12008 - Drug Profile 184
Cell Therapy for Graft Versus Host Disease - Drug Profile 185
Dendritic Cell Therapy for Immunology and Oncology - Drug Profile 186
Ha7 - Drug Profile 187
Drugs for Acute and Chronic GVHD - Drug Profile 188
ImmuneSafe - Drug Profile 189
Graft Versus Host Disease (GVHD) - Recent Pipeline Updates 190
Graft Versus Host Disease (GVHD) - Dormant Projects 257
Graft Versus Host Disease (GVHD) - Discontinued Products 258
Graft Versus Host Disease (GVHD) - Product Development Milestones 259
Featured News & Press Releases 259
Appendix 267
Methodology 267
Coverage 267
Secondary Research 267
Primary Research 267
Expert Panel Validation 267
Contact Us 268
Disclaimer 268

List of Tables
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2014 15
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Comparative Analysis by Unknown Stage Development, H2 2014 26
Products under Development by Companies, H2 2014 27
Products under Development by Companies, H2 2014 (Contd..1) 28
Products under Development by Companies, H2 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2014 30
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31
Graft Versus Host Disease (GVHD) - Pipeline by Biogen Idec Inc., H2 2014 32
Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2014 33
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2014 34
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 35
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2014 36
Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 37
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2014 38
Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals plc, H2 2014 39
Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014 40
Graft Versus Host Disease (GVHD) - Pipeline by Soligenix, Inc., H2 2014 41
Graft Versus Host Disease (GVHD) - Pipeline by NeoStem, Inc., H2 2014 42
Graft Versus Host Disease (GVHD) - Pipeline by Pharmacyclics, Inc., H2 2014 43
Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc., H2 2014 44
Graft Versus Host Disease (GVHD) - Pipeline by MediPost Co., Ltd., H2 2014 45
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2014 46
Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H2 2014 47
Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 48
Graft Versus Host Disease (GVHD) - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 49
Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H2 2014 50
Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2014 51
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 52
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2014 53
Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2014 54
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2014 55
Graft Versus Host Disease (GVHD) - Pipeline by Lycera Corp., H2 2014 56
Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2014 57
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2014 58
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd., H2 2014 59
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2014 60
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2014 61
Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2014 62
Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2014 63
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 64
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2014 65
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2014 66
Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2014 67
Graft Versus Host Disease (GVHD) - Pipeline by Spherium biomed S.L., H2 2014 68
Assessment by Monotherapy Products, H2 2014 69
Assessment by Combination Products, H2 2014 70
Number of Products by Stage and Target, H2 2014 73
Number of Products by Stage and Mechanism of Action, H2 2014 76
Number of Products by Stage and Route of Administration, H2 2014 78
Number of Products by Stage and Molecule Type, H2 2014 80
Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H2 2014 195
Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2014 262
Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2014 263